Skip to main content
. 2016 May 31;10(5):e0004739. doi: 10.1371/journal.pntd.0004739

Table 1. Clinical features of patients’ cohort.

Variable Cohort Distribution (quartiles)
Q1 Q2 Q3 Smallest Largest
Age 23 25 27 21 39
Height (cm) 163 169 175 157 184
Weight (kg) 63 67.5 78 55 115
BMI1 22.5 24.4 26.5 18.9 34.7
Evolution time2 16 32 48 10 192
Time for treatment3 (weeks) 5 8 12 3 60
Time from end of treatment 4 (weeks) 6.5 23 31 0** 113
Lesion area (cm2) 4.4 7.5 12 1.68 190*
Haemoglobin 15.6 16 16.9 13.7 17.6
White blood cells counting 6,070 7,500 8,700 4,000 11,310
Platelets 247,500 290,500 323,500 200,000 393,000
Lymphocyte (%) 25 33 43 12 58
Neutrophil (%) 46 50 60 23 72
Eosinophil (%) 2.8 4.5 6.6 1.2 12

1 Body mass index

2 Time (in weeks) between date of diagnosis confirmation and date of patient recruitment for the study

3 Elapsed time between the onset of symptoms and initiation of treatment with Glucantime

4 Time (in weeks) between date of treatment end and date of patient recruitment for the study

*Highest value corresponds to a lesion of 20 weeks of evolution on the right leg of a patient who presented multiple lesions and a BMI of 30.47

** Corresponding to a patient that was just ending the treatment without response during the time of the study recruitment